Table 1 Clinicopathological features of non-tumor-associated (NTA) and tumor-associated (TA) study groups

Patients, n

52

77

129

---

 Cleveland Clinic

9

25

34

---

 Rockford Clinic

20

19

39

---

 Stanford Univ.

3

6

9

---

 UW-Madison

20

27

47

---

Age (year)

60.3 (50–70)

61.3 (51–70)

60.9 (50–70)

0.22

PSA (ng/mL)*

7.0 (3.3–15.0)

5.8 (2.4–10.6)

6.3 (2.4–15.0)

< 0.01

PSA density (ng/mL)*

0.172 (0.06–0.43)

0.173 (0.06–0.40)

0.174 (0.06–0.43)

0.89

Prostate size (g)

46.6 (20–150)

36.3 (15–70)

40.3 (15–150)

< 0.01

BMI (kg/m²)*

29.69 (21.2–51.2)

29.11 (20.9–41.0)

29.34 (20.9–51.2)

0.69

Ethnicity:

---

 Caucasian

94.2% (49/52)

88.3% (68/77)

90.7% (117/129)

---

Family History:*

---

 Positive

25.0% (12/48)

35.6% (26/73)

31.4% (38/121)

---

DRE:*

---

 Positive

13.7% (7/51)

13.3% (10/75)

13.5% (17/126)

---

Grade Group (Gleason Score):

---

 2 (3 + 4)

---

36

36

---

 3 (4 + 3)

---

29

29

---

 4 (4 + 4)

---

4

4

---

 5 (4 + 5, 5 + 4)

---

8

8

---

Pathological stage:

---

 T2a

---

6

6

---

 T2b

---

9

9

---

 T2c

---

39

39

---

 T3a

---

18

18

---

 T3b

---

5

5

---